159 related articles for article (PubMed ID: 15746611)
1. [Feasability and tolerance of adjuvant treatment of melanoma with immunotherapy according to Kirkwood protocol].
Uwer L; Martin S; Geoffrois L; Schmutz JL
Ann Dermatol Venereol; 2005 Jan; 132(1):50-1. PubMed ID: 15746611
[No Abstract] [Full Text] [Related]
2. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
Schuchter LM
J Clin Oncol; 2004 Jan; 22(1):7-10. PubMed ID: 14665612
[No Abstract] [Full Text] [Related]
3. Adjuvant therapy for malignant melanoma.
Stoutenburg JP; Schrope B; Kaufman HL
Expert Rev Anticancer Ther; 2004 Oct; 4(5):823-35. PubMed ID: 15485316
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant interferon for melanoma.
Wheatley K; Ives N
Ann Oncol; 2002 Aug; 13(8):1319-20; author reply 1320. PubMed ID: 12181258
[No Abstract] [Full Text] [Related]
5. Adjuvant interferon in the treatment of melanoma.
Kirkwood JM
Br J Cancer; 2000 May; 82(10):1755-6. PubMed ID: 10817514
[No Abstract] [Full Text] [Related]
6. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.
Moschos SJ; Kirkwood JM; Konstantinopoulos PA
J Clin Oncol; 2004 Jan; 22(1):11-4. PubMed ID: 14665613
[No Abstract] [Full Text] [Related]
7. Feasibility of high-dose interferon-alpha2b adjuvant therapy for high-risk resected cutaneous melanoma.
Muggiano A; Mulas C; Fiori B; Liciardi G; Pintus M; Tanca L; Tedde A; Turno R; Desogus A
Melanoma Res; 2004 Apr; 14(2):S1-7. PubMed ID: 15057049
[TBL] [Abstract][Full Text] [Related]
8. [Cutaneous necrosis due to interferon alpha in a patient with melanoma].
Aguilar García G; Serrano Falcón C; Serrano Falcón Mdel M; Carmona MD; Linares Solano J; Serrano Ortega S
Actas Dermosifiliogr; 2006 Oct; 97(8):539-42. PubMed ID: 17067536
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant interferon therapy for malignant melanoma: the debate.
Zhou Q; Zhang XS
Chin J Cancer; 2010 Nov; 29(11):907-13. PubMed ID: 20979689
[TBL] [Abstract][Full Text] [Related]
10. The role of adjuvant interferon in high risk melanoma patients.
Dermatol Surg; 2000 Jun; 26(6):607-8. PubMed ID: 10848951
[No Abstract] [Full Text] [Related]
11. Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma.
Agarwala SS; Gray RJ; Wong MK
J Clin Oncol; 2009 Sep; 27(25):e82-3; author reply e84. PubMed ID: 19635995
[No Abstract] [Full Text] [Related]
12. High-dose adjuvant interferon therapy for melanoma.
Licata AG
Dermatol Nurs; 1998 Oct; 10(5):334-6. PubMed ID: 9873271
[TBL] [Abstract][Full Text] [Related]
13. Early signs of liver failure after low-dose interferon alfa-2b for cutaneous melanoma.
Ammoury A; El Sayed F; Farah C; Bazex J
J Am Acad Dermatol; 2008 Mar; 58(3):532-3. PubMed ID: 18280369
[No Abstract] [Full Text] [Related]
14. How does interferon work? Does it even matter?
Sondak VK
Cancer; 2002 Sep; 95(5):947-9. PubMed ID: 12209676
[No Abstract] [Full Text] [Related]
15. Comment on "Perhaps not everyone knows that...", (Ann Oncol 2001; 12: 1186).
Sulkes A; Schachter J
Ann Oncol; 2002 Apr; 13(4):637. PubMed ID: 12056717
[No Abstract] [Full Text] [Related]
16. [After removal of a malignant melanoma. Enhancing the immune system!].
MMW Fortschr Med; 1999 Nov; 141(44):66. PubMed ID: 10912153
[No Abstract] [Full Text] [Related]
17. [Interferons and malignant melanoma].
Dreno B
Rev Med Interne; 2002 Nov; 23 Suppl 4():489s-493s. PubMed ID: 12481404
[TBL] [Abstract][Full Text] [Related]
18. Lipoatrophy associated with interferon alfa adjuvant therapy for melanoma.
Vallés L; González M; Polo I; Enguita AB; Vanaclocha F; Ortiz-Romero PL
Arch Dermatol; 2009 Jan; 145(1):98-9. PubMed ID: 19153363
[No Abstract] [Full Text] [Related]
19. Impaired platelet aggregation in melanoma patients treated with interferon-alpha-2b adjuvant therapy.
Gutman H; Schachter J; Stopel E; Gutman R; Lahav J
Cancer; 2002 Feb; 94(3):780-5. PubMed ID: 11857313
[TBL] [Abstract][Full Text] [Related]
20. [Complete remission of Crohn's disease after high-dose alpha-interferon treatment for malignant melanoma].
Ferre Aracil C; Rodríguez de Santiago E; García García de Paredes A; Aguilera Castro L; Soria Rivas A; López SanRomán A
Gastroenterol Hepatol; 2016; 39(6):397-400. PubMed ID: 26096290
[No Abstract] [Full Text] [Related]
[Next] [New Search]
